These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
302 related items for PubMed ID: 25752497
1. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS. J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1905-12. PubMed ID: 25752497 [Abstract] [Full Text] [Related]
2. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. J Allergy Clin Immunol; 2014 Feb; 133(2):429-38. PubMed ID: 24269258 [Abstract] [Full Text] [Related]
3. Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands. Garritsen FM, van den Heuvel JM, Bruijnzeel-Koomen CAFM, Maitland-van der Zee AH, van den Broek MPH, de Bruin-Weller MS. J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1336-1342. PubMed ID: 29485224 [Abstract] [Full Text] [Related]
4. First experience with enteric-coated mycophenolate sodium (Myfortic) in severe recalcitrant adult atopic dermatitis: an open label study. van Velsen SG, Haeck IM, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Br J Dermatol; 2009 Mar; 160(3):687-91. PubMed ID: 19120337 [Abstract] [Full Text] [Related]
5. Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients. Pino Lopez J, Kromer C, Herr R, Schmieder A, Bayerl C, Schaarschmidt ML. Eur J Dermatol; 2021 Apr 01; 31(2):233-238. PubMed ID: 33871362 [Abstract] [Full Text] [Related]
6. Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis. Dias-Polak D, Bergman R, Avitan-Hersh E. J Dermatolog Treat; 2019 Feb 01; 30(1):49-51. PubMed ID: 29683760 [Abstract] [Full Text] [Related]
7. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara-Corrales I, Sugarman J, Tom W, Siegfried E, Cordoro K, Paller AS, Flohr C. J Am Acad Dermatol; 2017 Feb 01; 76(2):281-285. PubMed ID: 27855965 [Abstract] [Full Text] [Related]
8. [Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients]. Ballester I, Silvestre JF, Pérez-Crespo M, Lucas A. Actas Dermosifiliogr; 2009 Dec 01; 100(10):883-7. PubMed ID: 20038365 [Abstract] [Full Text] [Related]
9. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Clin Exp Allergy; 2004 Apr 01; 34(4):639-45. PubMed ID: 15080819 [Abstract] [Full Text] [Related]
10. Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs? Garritsen FM, Verheijen RHM, Gerestein CG, van Zuilen AD, Oosterhaven JAF, van Dijk M, Bruijnzeel-Koomen CAF, Schuttelaar ML, de Bruin-Weller MS. J Eur Acad Dermatol Venereol; 2018 Feb 01; 32(2):271-275. PubMed ID: 28925576 [Abstract] [Full Text] [Related]
11. Update on systemic therapies for atopic dermatitis. Denby KS, Beck LA. Curr Opin Allergy Clin Immunol; 2012 Aug 01; 12(4):421-6. PubMed ID: 22622476 [Abstract] [Full Text] [Related]
12. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. J Am Acad Dermatol; 2011 Jun 01; 64(6):1074-84. PubMed ID: 21458107 [Abstract] [Full Text] [Related]
13. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Murray ML, Cohen JB. Clin Exp Dermatol; 2007 Jan 01; 32(1):23-7. PubMed ID: 17059445 [Abstract] [Full Text] [Related]
14. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. Law Ping Man S, Bouzillé G, Beneton N, Safa G, Dupuy A, Droitcourt C. J Eur Acad Dermatol Venereol; 2018 Aug 01; 32(8):1327-1335. PubMed ID: 29444359 [Abstract] [Full Text] [Related]
15. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y. Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415 [Abstract] [Full Text] [Related]
16. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M. Transplant Proc; 2009 Nov 27; 41(9):3683-9. PubMed ID: 19917367 [Abstract] [Full Text] [Related]
17. Long-term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study. Védie AL, Ezzedine K, Amazan E, Boralevi F, Milpied B, Taïeb A, Seneschal J. Acta Derm Venereol; 2016 Aug 23; 96(6):802-6. PubMed ID: 26925822 [Abstract] [Full Text] [Related]
19. Systemic therapy of atopic dermatitis in children and adults. Simon D. Curr Probl Dermatol; 2011 Jul 23; 41():156-164. PubMed ID: 21576956 [Abstract] [Full Text] [Related]
20. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee SS, Steinbrecher UP, Yoshida EM. Liver Int; 2005 Aug 23; 25(4):723-7. PubMed ID: 15998421 [Abstract] [Full Text] [Related] Page: [Next] [New Search]